Sign In
Buy CYDY
$0.276
-0.0143 (-4.93%)
At Close: Jun 03, 2026
CytoDyn sees study of leronlimab preventing Simian Human Immunodeficiency virus published in scientific journal
09:48am, Monday, 07'th Jun 2021
CytoDyn Inc (OTCQB:CYDY) announced that the scientific journal Nature Communications published a study showing that leronlimab prevented nonhuman primates from being infected with Simian Human Immunod
Nature Communications Publishes Study of CytoDyn's Leronlimab Preventing HIV Infection in Primates
08:51am, Monday, 07'th Jun 2021
Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial
Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist
04:58pm, Sunday, 06'th Jun 2021
Finding trending penny stocks in 2021 can be difficult; here's 4 to help you on your search The post Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist appeared first on Penny Stocks to Buy,
CytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 Efforts
11:58pm, Wednesday, 02'nd Jun 2021
CytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 Efforts
CytoDyn wins first buy order from Chiral Pharma for using leronlimab for COVID-19 patients in the Philippines
12:42pm, Tuesday, 01'st Jun 2021
CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, revealed that Chiral Pharma Corporation placed its first purchase order for leronlimab under a co
VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR
Chiral is simultaneously working on application for Emergency Use Authorization
Wall Street higher at midday following US economic data
12:28pm, Thursday, 27'th May 2021
12:27pm: Nasdaq joins the other indices in the green In the US, the Dow was up 148 points, 0.4%, to 34,471 at midday. The Nasdaq added 31 points, 0.2%, to 13,769, and the S&P 500 improved 14 points,
Lawsuit: Investors bet big on Washington firm's potential COVID-19 treatment as CEO cashed out
10:30am, Thursday, 27'th May 2021
Investors in a biotech startup developing a COVID-19 treatment claim the firm's leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronavi
CytoDyn says Biomm SA to submit request to conduct Phase 3 clinical studies of leronlimab with ANVISA in Brazil
08:14am, Thursday, 27'th May 2021
CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, has said that its Brazilian distribution partner Biomm SA (BVMF:BIOM3) plans to submit an author
VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140)
CytoDyn taps Vice President, Corporate Controller Antonio Migliarese as its new CFO
08:32am, Friday, 21'st May 2021
CytoDyn Inc (OTCQB:CYDY) has found its new CFO in-house, promoting Vice President, Corporate Controller, Antonio Migliarese, the company announced. Migliarese joined CytoDyn in January 2020, and he
Antonio Migliarese Promoted to Chief Financial Officer of CytoDyn
04:55pm, Thursday, 20'th May 2021
VANCOUVER, Washington, May 20, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140)
CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines
02:36pm, Tuesday, 18'th May 2021
After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patien
CytoDyn to send topline results from severe coronavirus trial of leronlimab to regulators in India and the Philippines
09:57am, Tuesday, 18'th May 2021
CytoDyn Inc (OTCQB:CYDY) plans to submit the topline results of its CD12 Phase 3 clinical trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies,
